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Background: Interferon gamma release assays (IGRA) have been developed to support easy and fast diagnosis of
diseases like tuberculosis, and CMV in transplant patients. IGRAs focus on cellular immunity especially memory T
cells and thus also allow rapid screening prior to complex flow cytometric testing. Here, we describe a novel,
sensitive whole blood based cytokine release assay capable of assessing T cell responsiveness to HBV antigens in
Hepatitis B patients and assessing hepatitis B vaccination status in healthy individuals.
Methods: Seventy two chronic Hepatitis B patients (CHB), 8 acute hepatitis B patients (AHB) and 80 healthy
controls (HC) were tested by ELISA for IFNγ- and IL2-secretion in whole blood after challenge with synthetic
peptide libraries of hepatitis B core antigen (HBcAg) or hepatitis B surface antigen (HBsAg).
Results: The developed IGRA test reliably differentiated between Hepatitis B patients, vaccinees and unvaccinated
healthy controls. Treatment naïve and treated CHB patients showed a weaker IFNγ response to HBcAg (16 ± 5 and
35 ± 28 pg/ml, respectively) compared to the AHB group (82 ± 39 pg/ml), whereas HC remained unresponsive (6 ±
1 pg/ml). IL2 levels after HBcAg challenge were also higher in the AHB group compared to naive and treated CHB
as well as HC (47 ± 21 vs. 12 ± 3, 15 ± 10 and 12 ± 9 pg/ml, respectively). HBsAg stimulation led to increased IFNγ
and IL2 levels in the AHB group (33 ± 12 and 22 ± 12 pg/ml) and even higher levels in HC due to a high hepatitis B
vaccination rate (41 ± 10 and 167 ± 58 pg/ml). Naive and treated CHB patients developed no or only weaker IFNγ or
IL2 responses to HBsAg (5 ± 2 and 12 ± 7 pg/ml, for naive CHB, 12 ± 10 and 18 ± 15 pg/ml, for treated CHB). For
HC, IL2 release after HBsAg stimulation depicted hepatitis B vaccination status with a diagnostic sensitivity and
specificity of 85 % and 90 %.
Conclusion: Our novel whole blood based cytokine release assay constitutes an easy and robust tool for screening
HBV specific cellular immunity as alternative to flow cytometry or ELISPOT assays.
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More than 240 million individuals are infected with
chronic hepatitis B worldwide and are at risk to develop
severe liver disease, liver cirrhosis or hepatocellular car-
cinoma [1]. A prophylactic hepatitis B vaccine has been
available for over 3 decades and ensures long-term pro-
tection from infection [2]. However, development of a* Correspondence: w.dammermann@uke.de
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not met with success so far [3]. It is thought that one
reason for lacking efficacy of such a therapeutic vaccine
is that HBV-specific T lymphocytes show functional de-
fects and exhaustion and lack proliferation in chronic
hepatitis B [4, 5].
Effective prophylactic and therapeutic vaccines depend
on strong humoral and cellular immune responses to in-
fectious antigens as part of the vaccine formulation.
Whereas in vaccine trials the humoral immune response
is analyzed by standard serological assays, e.g. ELISA orccess article distributed under the terms of the Creative Commons Attribution
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ally assessed by established and technically demanding
analytical methods like flow cytometry, intracellular
cytokine staining (ICS), 3H-thymidine proliferation as-
says or ELISPOT [5]. Therefore, whole blood based cyto-
kine release assays or interferon gamma release assays
(IGRA), respectively, may constitute a robust, easy and
cost effective alternative as screening tools in studies of
HBV Immunology and HBV vaccination studies.
Here, we describe the establishment of a whole blood
based cytokine release assay capable of assessing T cell
responsiveness to HBV peptide pools in chronic hepa-




Hepatitis B patients treated at the hepatitis outpatient
department of the University Medical Center Hamburg-
Eppendorf were enrolled in the study for which all pa-
tients gave written consent and which was approved by
the Ethics Committee of the Hamburg Chamber of Phy-
sicians (PV3941). Patients were stratified according to
their clinical course into 3 groups (Table 1) with either
NUC treatment naïve chronic Hepatitis B (CHB, NUC
treatment naive, n = 40), NUC treated chronic Hepatitis
B (CHB, NUC treated, n = 32) or acute hepatitis B
(AHB, n = 8). NUC are nucleoside/nucleotide analogues
(NUC, tenofovir and/or entecavir) used for HBV specific
antiviral treatment. Healthy donors of the blood transfu-




Male 69 (86.3 %) 4 (50 %)
Female 11 (13.8 %) 4 (50 %)
Age (yr)a 40.6 ± 12.0 45.9 ± 15
Male 40.2 ± 12.1 49.7 ± 11.8
Female 43.7 ± 11.5 42.2 ± 18.7
ALT (U/l)a n.d.c 1046.0 ± 1
AST (U/l)a n.d.c 610.6 ± 70
HBV-DNA (IU/ml)a n.d.c 2.88*106 ±
HBsAg (IU/ml)a n.d.c 9153.4 ± 1
HBeAg Negative n.d.c 4 (50 %)
Positive n.d.c 4 (50 %)
Anti-HBs Negative 41 (51.2 %) 8 (100 %)
Positive 33 (41.3 %) 0 (0 %)
aThe data are shown as means ± standard deviations
bHC = healthy controls, AHB = acute hepatitis B, CHB = chronic hepatitis B
cn.d. = not determinedEppendorf were anonymously enrolled in the study as
healthy controls (HC, n = 80). Additional clinical data
for all patients and HC was provided (Table 1).
Reagents
The recall peptide pool CEFT was purchased from JPT,
Germany (#PM-CEFT) and solved in sterile dimethyl
sulfoxide (DMSO; #RO/A9941/000100, Th. Geyer,
Germany) 25 mg/ml followed by storage at −20 °C.
CEFT peptide pool consisted of antigenic peptides from
human Cytomegalovirus (HHV-5; CMV), Epstein-Barr
virus (HHV-4; EBV), Influenza A and Clostridium tetani.
This positive control pool contained 27 peptides selected
from defined HLA class I and II-restricted T-cell epi-
topes. Considering the high vaccination frequency
against Influenza and C.tetani and the high prevalence
of CMV and EBV in the general population in Germany
recall antigen responses were expected for all patient
samples. Staphylococcus aureus enterotoxin B superanti-
gen (SEB) was obtained from Sigma Aldrich GmbH,
Germany (#S4881) and stored 1 mg/ml in sterile,
endotoxin-free H2O and −20 °C. Synthetic HBV peptide
libraries of HBcAg and HBsAg were purchased from
JPT, Germany (#PM-HBV-CP and #PM-HBV-lEP, re-
spectively) and solved in sterile dimethyl sulfoxide
(DMSO; #RO/A9941/000100, Th. Geyer, Germany)
50 mg/ml followed by storage at −20 °C. Synthetic
HBcAg represented a mix of 44 peptides (15 amino acid
length each, 11 aa overlap, peptide scan 15/11) compris-
ing the whole amino acid sequence of HBcAg, the
21.5 kDa capsid protein of HBV (genotype A2 subtypeCHBb, NUC treatment naive CHBb, NUC treated
40 32
20 (50 %) 23 (71.9 %)
20 (50 %) 9 (28.1 %)
43.4 ± 14.9 47.3 ± 11.4
41.2 ± 11.6 50.1 ± 11.2
45.7 ± 17.6 40.0 ± 8.6
035.0 37.7 ± 60.2 42.9 ± 39.3
2.5 26.6 ± 27.9 29.5 ± 27.7
7.7*106 4.2*107 ± 1.8*108 1.6*107 ± 8.8*107
0,378.9 12,588.6 ± 20,958.8 4783.1 ± 6326.3
34 (85 %) 24 (77.4 %)
6 (15 %) 7 (22.6 %)
36 (90 %) 32 (100 %)
4 (10 %) 0 (0 %)
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mix of 98 peptides (15 amino acid length each, 11 aa
overlap, peptide scan 15/11) comprising the whole
amino acid sequence of HBsAg, the 43.7 kDa surface
protein of HBV (genotype A2 subtype adw2, UniProt:
P17101).
Cytokine release assay in whole blood ex vivo
Venous blood was collected from hepatitis B patients
and HC into sterile 7.5 ml Lithium heparin Monovettes
(Sarstedt, Germany). 1 ml of whole blood was then dis-
pensed into sterile, pyrogen free 2 ml tubes with screw
caps (Sarstedt, Germany) within 4 h of collection pre-
loaded with sterile 0.9 % (w/v) NaCl solution (negative
control), SEB (1st positive control), recall CEFT peptide
pools (2nd positive control) or HBV peptide pools. In all
tubes, glucose (2 mg/mI final concentration; pre-diluted
in sterile 0.9 % (w/v) NaCl solution; #HN06.1, Carl Roth,
Germany) was used to further enhance cytokine secre-
tion, which had been tested before using various anti-
gens (Additional file 1: Online resource 1).
Thus, whole blood was stimulated with a total volume
of 120 μl/ tube of NaCl & glucose (negative control),
120 μl/ tube SEB & glucose (1 μg/ml final concentration
after dilution out of stock, 1st positive control), 120 μl/
tube recall antigen CEFT & glucose (10 μg/ml final con-
centration after dilution out of stock, 2nd positive con-
trol) or 120 μl/ tube HBV peptide pools (50 μg/ml final
concentration after dilution out of stock). All HBV pep-
tide pools were titrated for maximum cytokine responses
in advance. SEB served as a 1st positive control due to
its superantigenic properties by cross-linking MHC mol-
ecules with T-cell receptors, which proved the general
viability of all samples. CEFT was introduced as a 2nd
positive control to prove the functionality of antigen
presenting cells in all samples.
The tubes were closed and incubated at 37 °C for
24 h. Thereafter, plasma supernatants were aspirated,
pooled, stabilized with 0.045 % (w/v) NaN3 and stored
at −20 °C until assayed for cytokines within the next
7 days. A 5 % (v/v) CO2 atmosphere was proven to be
unnecessary (data not shown) and yielded results com-
parable to stimulation in the presence of CO2.
IFNγ and IL2 ELISAs
Detection of total / overall amounts of IFNγ and IL2 in
human plasma was conducted using ELISA MAX De-
luxe sets from Biolegend, Germany: IFNγ (#430106) and
IL2 (#431806). The manufacturer’s Avidin-horseradish
peroxidase conjugate was replaced by PolyHRP80 strep-
tavidine conjugate (#SP80C, SDT Reagents, Germany) in
order to achieve a tenfold lower limit of detection.
Lower limit of detection (Background + 3x S.D.) was
generally at 2 – 5 pg/ml for IFNγ and IL2, respectively.Initial dilution of control and test samples was per-
formed described as follows: negative control (NaCl)
1/5, 1st positive control (SEB) 1/2500 for IFNγ and
1/500 for IL2, 2nd positive control (CEFT) 1/50 for IFNγ
and 1/25 for IL2, test samples (HBcAg and HBsAg) 1/5.
If a test sample’s absorbance value fell outside the max-
imum standard curve range, these samples were sub-
sequently retested with a tenfold higher dilution, e.g.
1/5→ 1/50, 1/500→ 1/5000, 1/2500→ 1/25000. A
seven-point standard curve from 1 – 64 pg/ml IFNγ or
IL2 was used for quantitation. Standards, controls and
test samples were measured in duplicate. The samples
were analyzed using Magellan software (version 6.5)
equipped on a Tecan M200 plate reader.
Data analysis
Software
The ELISA data was analyzed using SigmaPlot software
(Systat Software Inc., version number 12.2) and Graph-
Pad Prism software (Graphpad Software Inc., version
number 6.04).
Statistical analysis
Descriptive statistics, ANOVA including Tamhane T2
post hoc tests and prior normality tests, unpaired t-test
and receiver operating characteristic (ROC) analysis
were performed using SPSS Statistics software (IBM,
version number 22), SigmaPlot software (Systat software
Inc., version number 12.2) and GraphPad Prism software
(Graphpad Software Inc., version number 6.04). Negative
control values were deducted from the peptide induced
responses prior to statistical analysis. Intra-assay and
inter-assay variability could not be assessed due to lim-
ited amounts of whole blood per patient.
Results
IFNγ responses to HBcAg in whole blood of CHB patients
are reduced compared to AHB patients
Two major HBV proteins, HBcAg and HBsAg, were
tested in an HBV specific cytokine release assay with HC
and 3 different hepatitis B patient groups: acute, NUC
treatment naïve and NUC treated chronic hepatitis B.
Stimulation of whole blood with sterile 0.9 % (w/v) NaCl
solution (negative control), SEB (1st positive control)
and CEFT (2nd positive control) confirmed the viability
of all collected samples (Fig. 1. and Table 2).
Synthetic HBcAg-specific peptides elicited higher IFNγ
responses in AHB than treatment naïve and treated
CHB patients (Fig. 2a, Table 3; 82 ± 39 vs. 16 ± 5 and
35 ± 28 pg/ml; p = 0.78 and p = 0.98). HC did not show
any reaction towards HBcAg in whole blood compared
to AHB patients (6 ± 1 vs. 82 ± 39 pg/ml, p = 0.62). Syn-
thetic HBsAg peptides induced comparable IFNγ
responses in HC and AHB patients (Fig. 2a; 41 ± 10 vs.
Fig. 1 HC and hepatitis B patients show comparable and distinct
IFNγ and IL2 responses in whole blood towards control stimulations
with SEB and CEFT. n = 80 HC, n = 8 AHB patients, n = 40 NUC
treatment naive CHB patients and n = 32 NUC treated patients, for
each tested control antigen. Every HC or patient was tested against
buffer control, SEB and CEFT. (a) IFNγ, (b) IL2. Negative control
values were deducted from the antigen induced responses. Lower
limit of detection (Background + 3x S.D.) was at 2 – 5 pg/ml for IFNγ
and IL2. All values are given as mean concentration pg/ml ± S.E.M.
ANOVA and Tamhane T2 post hoc tests, following symbol pinpoints
significant differences: *. One symbol equals 0.05, two symbols 0.01,
three symbols 0.001
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as well as treated CHB patients (5 ± 2 and 12 ± 10 pg/ml;
naïve CHB vs. HC p = 0.003 and naïve CHB vs. AHB
p = 0.46; treated CHB vs. HC p = 0.28 and treated CHB
vs. AHB p = 0.9).
IL2 responses were generally comparable to IFNγ re-
sponses regarding total cytokine amounts (Fig. 2b).
HBcAg induced IL2 synthesis in AHB (47 ± 21 pg/ml),
but not naïve and treated CHB patients as well as HC
(12 ± 3, 15 ± 10 and 12 ± 9 pg/ml; p = 0.78, p = 0.89 and
p = 0.82). HBsAg elicited significantly higher IL2Table 2 Positive and negative controls
Assay NaCl (negative control)a SEB (1.
IFNγ [pg/ml] IL2 [pg/ml] IFNγ [p
Group
HCb 8 ± 2 2 ± 1 66,537 ±
AHBb 15 ± 5 3 ± 1 45,083 ±
CHBb, NUC treatment naive 41 ± 22 1 ± 1 65,734 ±
CHBb, NUC treated 17 ± 6 2 ± 1 107,200
aThe data are shown as means ± standard error of mean (S.E.M.). SEB and CEFT valu
bHC = healthy controls, AHB = acute hepatitis B, CHB = chronic hepatitis Bresponses in HC (167 ± 58 pg/ml) compared to AHB,
naïve and treated CHB patients (22 ± 12, 12 ± 7 and
18 ± 15 pg/m; p = 0.05, p = 0.03 and p = 0.04).
Taken together, cytokine release assays using HBcAg
stimulation in whole blood are able to depict the (hypo-)
responsiveness of HBV-specific T cells in CHB patients.
HBeAg + CHB patients show weaker cytokine responses
to HBcAg and HBsAg than HBeAg- CHB patients
All NUC treatment naïve and NUC treated 72 CHB pa-
tients were stratified according to HBeAg status as well
as HBV-DNA status and subsequently tested for IFNγ-
and IL2-secretion in whole blood after challenge with
synthetic HBcAg- and HBsAg-specific peptides by
ELISA. Stimulation with HBcAg-specific peptides led to
higher IFNγ concentrations in plasma of treated, but not
naive HBeAg- CHB patients compared to HBeAg + pa-
tients (Fig. 3a - b; 17 ± 6 vs. 12 ± 9 pg/ml for naïve CHB;
46 ± 37 vs. 3 ± 1 pg/ml for treated CHB, respectively).
Stimulation with HBsAg-specific peptides was also more
prominent in treated, but not naive HBeAg- CHB pa-
tients compared to HBeAg + patients (6 ± 2 vs. 1 ± 1 pg/
ml for naïve CHB and 16 ± 13 vs. 1 ± 1 pg/ml for treated
CHB, respectively). IL2 responses yielded a comparable
pattern with stronger cytokine production in plasma of
HBeAg- CHB patients compared to HBeAg + patients:
treated HBeAg- CHB patients gave higher IL2 levels
than HBeAg + CHB patients (Fig. 3d; 20 ± 13 vs. 1 ±
1 pg/ml for HBcAg and 24 ± 20 vs. 1 ± 1 pg/ml for
HBsAg, respectively), whereas effects of HBcAg and
HBsAg stimulation on IL2 levels in plasma of naïve
CHB patients were negligible (Fig. 3c).
Regarding HBV-DNA status we looked for effects of
viral load on the cytokine responses directed against
HBcAg and HBsAg, but unlike HBeAg status viral load
did not seem to influence cytokine production in a simi-
lar fashion: low HBV-DNA titers ≤ 50 IU/ml did not al-
ways coincide with higher cytokine levels after HBcAg
or HBsAg stimulation in treatment naïve and NUC
treated CHB patients (Fig. 3e – h).
In conclusion, HBeAg + treatment naïve and NUC
treated CHB patients showed the weakest cytokinepositive control)a CEFT (2. positive control)a
g/ml] IL2 [pg/ml] IFNγ [pg/ml] IL2 [pg/ml] N
8485 22,762 ± 1399 1681 ± 361 125 ± 36 80
14,487 10,737 ± 2148 458 ± 278 22 ± 11 8
8837 18,439 ± 1244 1490 ± 669 220 ± 173 40
± 30,799 20,838 ± 1357 3186 ± 1383 318 ± 293 32
es are given after deduction of background values (NaCl, negative control)
Fig. 2 Synthetic HBcAg peptides elicit weak IFNγ and IL2 responses
during HBV-specific T cell stimulation in whole blood of CHB patients.
n = 80 HC, n = 8 AHB patients, n = 40 NUC treatment naive CHB
patients and n = 32 NUC treated patients, for each tested HBV
antigen. Every HC or patient was tested against HBV peptide pools
specific for HBcAg and HBsAg. (a) IFNγ, (b) IL2. Negative control
values were deducted from the peptide induced responses. Lower
limit of detection (Background + 3x S.D.) was at 2 – 5 pg/ml for
IFNγ and IL2. All values are given as mean concentration pg/ml ±
S.E.M. ANOVA and Tamhane T2 post hoc tests, following symbol
pinpoints significant differences: *. One symbol equals 0.05, two
symbols 0.01, three symbols 0.001
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all hepatitis B patient groups.
Treatment naïve CHB patients show comparable cytokine
responses to HBcAg and HBsAg compared to NUC treated
CHB patients in whole blood
72 CHB patients were stratified according to treatment
status with nucleoside/nucleotide analogues (NUC, teno-
fovir and/or entecavir) and subsequently tested for
IFNγ- and IL2-secretion in whole blood after challenge
with synthetic HBcAg and HBsAg peptides by ELISA.Table 3 HBcAg and HBsAg stimulations
Assay HBcAga
IFNγ [pg/ml] IL2 [pg/
Group
HCb 6 ± 1 12 ± 9
AHBb 82 ± 39 47 ± 2
CHBb, NUC treatment naive 16 ± 5 12 ± 3
CHBb, NUC treated 35 ± 28 15 ± 1
aThe data are shown as means ± standard error of mean (S.E.M.). HBcAg and HBsAg
bHC = healthy controls, AHB = acute hepatitis B, CHB = chronic hepatitis BHBcAg and HBsAg stimulation did not result in sig-
nificant differences regarding IFNγ concentrations in
plasma of treatment naïve patients compared to NUC
treated patients (Fig. 4a; 16 ± 5 vs. 35 ± 28 pg/ml for
HBcAg and 5 ± 2 vs. 12 ± 10 pg/ml for HBsAg, respect-
ively). Likewise, IL2 responses to HBcAg and HBsAg in
whole blood yielded no significant differences in view to
treatment status (Fig. 4b; 12 ± 3 vs. 15 ± 1 pg/ml for
HBcAg and 12 ± 10 vs. 18 ± 15 pg/ml for HBsAg,
respectively).
NUC treatment had no significant positive effect on
cytokine release in whole blood after stimulation with
HBcAg and HBsAg-specifc peptides ex vivo.
IL2 responses to HBsAg in HC correlate with hepatitis B
vaccination status
HBsAg constitutes the single main antigen in hepatitis B
vaccine formulations. Thus, 74 HC with known hepatitis
B vaccination status were also analyzed regarding their
HBsAg-dependent IFNγ and IL2 release. 33/74 HC pos-
sessed a positive anti-HBs antibody titer and 41/74 were
anti-HBs negative. Whereas IFNγ responses were negli-
gible, IL2 values reached marked heights if the tested in-
dividual had been successfully vaccinated (Fig. 5b), but
these IL2 levels did not correlate with the corresponding
anti-HBs antibody titer (Fig. 6). To determine the cut-off
value of our newly developed assay, we performed a
ROC analysis of the IL2 readings (Fig. 5a). This HBV
specific cytokine release assay with HBsAg-specific pep-
tides using IL2 release as the primary readout (cut-off =
11 pg/ml IL2) reached 85 % diagnostic sensitivity and
90 % diagnostic specificity. The corresponding AUC
value was at 0.92. Using the cut-off defined by the ROC
analysis, as shown in Fig. 4, 28 (of 33) vaccinated HC
showed positive scores, while 4 (of 41) not vaccinated
HC slightly exceeded the cut-off value (Fig. 5b).
Discussion
Cytokine release assays using whole blood depict (hypo-)
responsiveness of HBV-specific T cells in CHB patients
The group of Boni et al. delivered key data regarding the
HBV specific cellular immune status under treatmentHBsAga
ml] IFNγ [pg/ml] IL2 [pg/ml] N
41 ± 10 167 ± 58 80
1 33 ± 12 22 ± 12 8
5 ± 2 12 ± 7 40
0 12 ± 10 18 ± 15 32
values are given after deduction of background values (NaCl, negative control)
Fig. 3 HBeAg + CHB patients show weaker cytokine responses against HBcAg and HBsAg than HBeAg- CHB patients. (a) – (d) n = 40 NUC
treatment naïve CHB patients with n = 6 HBeAg + and n = 34 HBeAg-. n = 32 NUC treated CHB patients, with n = 6 HBeAg + and n = 26 HBeAg-.
(e) – (h) n = 40 NUC treatment naïve CHB patients with n = 10 HBV-DNA ≤50 IU/ml and n = 30 HBV-DNA >50 IU/ml. n = 32 NUC treated CHB
patients, with n = 22 HBV-DNA ≤50 IU/ml and n = 10 HBV-DNA >50 IU/ml. Every patient was tested against HBV antigens HBcAg and HBsAg.
(a), (b), (e) and (f) IFNγ, (c), (d), (g) and (h) IL2, respectively. Negative control values were deducted from the antigen induced responses. Lower
limit of detection (background + 3x S.D.) was at 2 – 5 pg/ml for IFNγ and IL2. All values are given as mean concentration pg/ml ± S.E.M. Unpaired
t-test, following symbol pinpoints significant differences: *. One symbol equals 0.05, two symbols 0.01, three symbols 0.001, n.s. not significant
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Fig. 4 NUC treated CHB patients show comparable cytokine responses to HBcAg and HBsAg compared to treatment naïve CHB patients in whole
blood. Lower limit of detection (Background + 3x S.D.) was at 2 – 5 pg/ml for IFNγ and IL2. n = 72 CHB patients, whereas n = 40 NUC treatment
naive and n = 32 NUC treated. Every patient was tested against HBV antigens HBcAg and HBsAg. (a) IFNγ, (b) IL2. Negative control values were
deducted from the antigen induced responses. All values are given as mean concentration pg/ml ± S.E.M. Unpaired t-test, following symbol
pinpoints significant differences: *. One symbol equals 0.05, two symbols 0.01, three symbols 0.001, n.s. not significant
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fovir and entecavir) in consecutive and longitudinal clin-
ical studies on HBV specific cellular immunity in CHB
patients [4, 5]. In most cases a restoration of anti-viral T
cell responses could be observed after in vitro expansion,
but not directly ex vivo [4, 5].
Our current results mirror these findings, since no sig-
nificant recovery of the cytokine responses to HBcAg and
HBsAg could be observed in NUC treated CHB patients
in whole blood ex vivo. Interestingly, we detected the
strongest IFNγ and IL2 responses to HBcAg stimulation
in a small pilot group of resolved hepatitis B patients
(109 ± 27 and 309 ± 143 pg/ml, n = 3) that we measured
for exploratory reasons compared to all other groups,
whereas the IL2 response to HBsAg was negligible in con-
trast to HC (35 ± 4 vs 165 ± 58 pg/ml). It will be intriguing
to further analyze this group of patients in follow-up stud-
ies i.e. to understand in how far the size of the immune re-
sponse in our assays can predict patients that are at risk of
HBV reactivation under immune suppression.
This suppressed T cell state is ongoing even after initi-
ating successful treatment probably due to initially highFig. 5 IL2 responses to HBsAg in HC correlate with hepatitis B vaccination
under the curve. (b) Scatter plot of IL2 release of HepB vaccinated and not
control values were deducted from the antigen induced responses. Dotted
anti-HBs positive and n = 41 anti-HBs negativeviral or antigen load and might partially explain why
clinical trials with therapeutic hepatitis B vaccines and
anti-viral drugs have not been effective so far, whereas
treatment safety was generally achieved [8–11]. In these
studies, HBV-specific cell mediated immunity and espe-
cially the T cell (hypo)-responsiveness of CHB patients
was analyzed by established techniques, e.g. flow cytome-
try, intracellular cytokine staining (ICS), 3H-thymidine
proliferation assays or ELISPOT.
We have demonstrated the suitability of whole blood
based cytokine release assays to analyze T cell (hypo-) re-
sponsiveness in CHB patients and were even able to differ-
entiate the suppressed T cell state further into HBeAg +
CHB patients with stronger suppression than HBeAg-
CHB patients. Thus, we propose our protocol as an add-
itional easy-to-use, cost efficient and robust tool for future
therapeutic hepatitis B vaccination studies.
IL2 responses after HBsAg-specific peptide stimulation
allow assessment of Hepatitis B vaccination status in HC
Another important aspect of hepatitis B vaccination
studies is the emergence of non- and low-responders tostatus. (a) Receiver-operating-characteristic (ROC) curve. AUC, area
vaccinated HC after HBsAg stimulation of whole blood. Negative
line indicates IL2 cut-off at 11 pg/ml. n = 74 HC, whereas n = 33 were
Fig. 6 Anti-HBs titers and strength of IL2 response do not correlate
in hepatitis B vaccinated HC. Scatter plot of IL2 release of HepB
vaccinated HC after HBsAg stimulation vs. anti-HBs titers. Negative
control values were deducted from the antigen induced responses.
Continuous line indicates linear regression and Pearson correlation.
R2: coefficient of determination
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subjects who lost their protective anti-HBs titers over
time [12, 13]. In these cases the question arises whether
hepatitis B immunity is completely absent with no
humoral and cellular immunologic memory or only par-
tial, namely with hepatitis B specific cellular immunity
present. The group of Bauer and Jilg proved the pres-
ence of significant numbers of HBsAg-specific memory
T and B cells in a group of 15 healthy individuals who
were successfully vaccinated but had lost anti-HBs titers
[13]. A different study used a prototypic third generation
HBV vaccine, Sci-B-Vac™, containing small S, PreS1 and
PreS2 antigens to trigger cellular and humoral immunity
in healthy individuals who failed immunization with
conventional vaccines [12]. 15 non-responders and 6
low-responders were included. After three vaccinations, 20/
21 subjects developed protective anti-HBs titers ≥10 IU/l,
whereas 8/15 non-responders and 5/6 low-responders
showed HBsAg-specific T cell immunity using proliferation
assays and IFNγ release assays.
In these studies 3H-thymidine proliferation assays or
IFNγ ELISPOT assays were used to analyze HBV-
specific cell-mediated immunity. Both assay types repre-
sent well-established techniques using lymphocytes
isolated from peripheral blood (PBMCs). However, the
direct use of whole blood ex vivo and the cytokine IL2
as a novel T cell readout marker might be an attractive
alternative in case of future hepatitis B vaccination stud-
ies. Our results clearly depicted the hepatitis B vaccin-
ation status in healthy individuals and thus should be
considered equal to the aforementioned techniques.
Interestingly, a strong IL2 response was not mirrored by
an equally high antibody titer thus adding valuable infor-
mation on the immune status. Integrating both humoraland cellular data potentially could give us critical in-
sights regarding overall humoral and cellular immunity
towards HBV.
We propose our assay as fast and cost-effective tool
for initial screenings of specimen to identify specific can-
didates which could then subsequently be tested by
more technically demanding analytical methods like flow
cytometry or ELISPOT.
Conclusion
We have established a protocol which is capable of ana-
lyzing the responsiveness of HBV-specific T cells in pa-
tients with chronic hepatitis B infection using whole
blood directly for testing without further sample prepar-
ation. In addition, we are able to assess the hepatitis B
vaccination status of healthy blood donors on the cellu-
lar immunity level.
This novel IGRA constitutes an additional easy-to-use,
cost-efficient and robust tool for screening HBV specific
cellular immunity alone or in addition to other more
technically demanding follow-up analytical methods like
flow cytometry or ELISPOT.
Additional file
Additional file 1: Online Resource 1 Glucose supplementation to
whole blood from HC enhances cytokine secretion during antigen
responses. Stimulations were performed with (a) & (d) VZV antigen
peptide pools gE and IE63 (b) & (e) mumps virus lysate or (c) & (f)
glucose only. Lower limit of detection (background + 3x S.D.) was at
2 – 5 pg/ml for IFNγ and IL2. Only varicella zoster virus (VZV) and mumps
virus seropositive HC are shown. All values are given as single concentration
pg/ml. Blue lines indicate median concentrations. Reproducibility was
ensured by applying every antigen in two independent experiments with
n = 3+ HC per experiment.
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